Reflections on the COVID-19 pandemic from a university academic
Ian Macreadie
+ Author Affiliations
- Author Affiliations
School of Science, RMIT University, Bundoora, Vic. 3083, Australia. Tel.: +61 402 564 308; Email: ian.macreadie@rmit.edu.au
Microbiology Australia 42(3) 138-140 https://doi.org/10.1071/MA21038
Published: 7 September 2021
Journal Compilation © CSIRO 2021 Open Access CC BY, published (by CSIRO Publishing) on behalf of the ASM
References
[1] Selleck, P. and Barnard, R. (2020) The 1918 Spanish influenza pandemic: plus ça change, plus c’est la même chose. Microbiol. Aust. 41, 177–182.| The 1918 Spanish influenza pandemic: plus ça change, plus c’est la même chose.Crossref | GoogleScholarGoogle Scholar |
[2] Boath, J.M. et al. (2020) Polyphasic characterisation of Cedecea colo sp. nov., a new enteric bacterium isolated from the koala hindgut. Microorganisms 8, 309.
| Polyphasic characterisation of Cedecea colo sp. nov., a new enteric bacterium isolated from the koala hindgut.Crossref | GoogleScholarGoogle Scholar |
[3] Lloyd, M. (2020) ASM Virtual EduCon 2020. Microbiol. Aust. 41, 163–165.
| ASM Virtual EduCon 2020.Crossref | GoogleScholarGoogle Scholar |
[4] Britz, M. (2010) A tribute to Professor Arnold L Demain – a lifetime in industrial microbiology. Microbiol. Aust. 31, 97–100.
| A tribute to Professor Arnold L Demain – a lifetime in industrial microbiology.Crossref | GoogleScholarGoogle Scholar |
[5] Mackenzie, J.S. and Smith, D.W. (2020) COVID-19: a novel zoonotic disease caused by a coronavirus from China: what we know and what we don’t. Microbiol. Aust. 41, 45–50.
| COVID-19: a novel zoonotic disease caused by a coronavirus from China: what we know and what we don’t.Crossref | GoogleScholarGoogle Scholar |
[6] Zimmerman, R.K. (2021) Helping patients with ethical concerns about COVID-19 vaccines in light of fetal cell lines used in some COVID-19 vaccines. Vaccine 39, 4242–4244.
| Helping patients with ethical concerns about COVID-19 vaccines in light of fetal cell lines used in some COVID-19 vaccines.Crossref | GoogleScholarGoogle Scholar |
[7] Young, P.R. (2020) Disease X ver. 1.0: COVID-19. Microbiol. Aust. 41, 109–112.
| Disease X ver. 1.0: COVID-19.Crossref | GoogleScholarGoogle Scholar |
[8] De Clercq, E. (2021) Perspectives for antivirals to limit SARS-CoV-2 infection (COVID-19) Microbiol. Aust. 42, 47–53.
| Perspectives for antivirals to limit SARS-CoV-2 infection (COVID-19)Crossref | GoogleScholarGoogle Scholar |
[9] Singh, K.P. et al. (2020) Therapeutics for COVID-19: established and in development Microbiol. Aust. 41, 217–223.
| Therapeutics for COVID-19: established and in developmentCrossref | GoogleScholarGoogle Scholar |
